Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: Results of a phase II study

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 408-414

  Friedlander, Terence W ^a   Weinberg, Vivian K ^a   Small, Eric J ^a   Sharib, Jeremy ^a   Harzstark, Andrea L ^a   Lin, Amy M ^a   Fong, Lawrence ^a   Ryan, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLURRED VISION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FLATULENCE; HEADACHE; HUMAN; HYPERKALEMIA; INTERNATIONAL NORMALIZED RATIO; INTRAOCULAR HEMORRHAGE; LIVER CONGESTION; MALE; MULTIPLE CYCLE TREATMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; RADIOGRAPHY; SCLERA HEMORRHAGE; SIDE EFFECT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE; FLATULENCE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; OCTREOTIDE; ORCHIECTOMY; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863008927     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.06.014     Document Type: Article

References (27)

1. Kaplan P.J., Mohan S., Cohen P., et al. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999, 59:2203-2209.
2. Nickerson T., Miyake H., Gleave M.E., et al. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 1999, 59:3392-3395.
3. Kimura T, Kuwata T, Ashimine S, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 16:121-9.
4. Burfeind P., Chernicky C.L., Rininsland F., et al. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996, 93:7263-7268.
5. Rajah R., Valentinis B., Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997, 272:12181-12188.
6. Perks C.M., Newcomb P.V., Norman M.R., et al. Effect of insulin-like growth factor binding protein-1 on integrin signaling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol 1999, 22:141-150.
7. Hamy F., Brondani V., Spoerri R., et al. Specific block of androgen receptor activity by antisense oligonucleotides. Prostate Cancer Prostatic Dis 2003, 6:27-33.
8. Nickerson T., Chang F., Lorimer D., et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001, 61:6276-6280.
9. Chan J.M., Stampfer M.J., Ma J., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002, 94:1099-1106.
10. Platz E.A., Pollak M.N., Leitzmann M.F., et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005, 16:255-262.
11. Mantzoros C.S., Tzonou A., Signorello L.B., et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997, 76:1115-1118.
12. Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998, 90:911-915.
13. Koutsilieris M., Mitsiades C.S., Bogdanos J., et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004, 10:4398-4405.
14. Logothetis C.J., Hossan E.A., Smith T.L. SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 1994, 14:2731-2734.
15. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
17. Gill JK, Wilkens LR, Pollak MN, et al. Androgens, growth factors, and risk of prostate cancer: The Multiethnic Cohort. Prostate.
18. Thomas R., Kim M.H. A HIF-1α-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells. Prostate 2009, 69:263-275.
19. Thomas R., Kim M.H. HIF-1 α: A key survival factor for serum-deprived prostate cancer cells. Prostate 2008, 68:1405-1415.
20. Kelley K.M., Oh Y., Gargosky S.E., et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996, 28:619-637.
21. Collett-Solberg P.F., Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996, 25:591-614.
22. Yu H., Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000, 92:1472-1489.
23. Kalkner K.M., Acosta S., Thorsson O., et al. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:92-98.
24. Schmid H.P., Gregorin J., Altwein J.E. Growth hormone inhibitors in prostate cancer: A systematic analysis. Urol Int 2008, 81:17-22.
25. Lamberts S.W., de Herder W.W., Hofland L.J. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002, 13:451-457.
26. Joensuu T.K., Nilsson S., Holmberg A.R., et al. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer. Ann NY Acad Sci 2004, 1028:361-374.
27. Maulard C., Richaud P., Droz J.P., et al. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995, 36:259-262.